sirolimus, 8 frSES with 1 mg/mm 2 of sirolimus and 8 bare metal stents.
BACKGROUND Percutaneous coronary intervention (PCI) of coronary calcified lesions has been associated with worse clinical outcomes compared to non-calcified lesions. However, the impact of coronary calcifications (CC) two years after drug-eluting stent (DES) PCI is unknown. We sought to evaluate the frequency and impact of CC two years after DES PCI from the large ADAPT-DES registry.
METHODS ADAPT-DES was a prospective, multicenter "all-comers" registry of consecutive patients successfully treated with at least one DES. Two-year outcomes were analyzed according to the presence of CC as assessed by the enrolling site operator.
RESULTS A total of 8,578 patients underwent DES PCI; CC of at least one target lesion was present in 2,646 patients (30.8%). Patients with CC were older, more frequently had diabetes, hypertension, dyslipidemia, renal insufficiency, left main or LAD disease, and multivessel intervention, with more stents implanted. IVUS was used equally in both groups. Second-generation DES were implanted less frequently among patients with CC (60.5% vs. 64.7%, p¼0.0002). At two years, CC patients had higher unadjusted rates of adverse ischemic and bleeding events (Table) . By multivariable analysis, the presence of CC was a strong independent predictor of death (HR Table. In ERACI IV MACCE at 1 year was 2.2%, duplicating this number up to 5.8% at 20 months, although compared to ERACI III, ERACI IV has lower incidence of MACCE (p<0.001), the same outcome was seen in diabetics (5.8% vs 25.5%, ERACI IV vs ERACI III respectively, p<0.001) and non-diabetics (5.8% vs 12.4%, respectively p< 0.02) METHODS Thirty patients with symptomatic ischemic heart disease and a single de novo native coronary lesion suitable for percutaneous coronary intervention were prospectively enrolled at 4 New Zealand sites. Lesion length had to be <23 mm and the vessel reference diameter 2.5-3.5 mm. The primary safety endpoint was 6-month target vessel failure (TVF), defined as the composite of death, target vessel MI or clinically-driven target vessel revascularization (TLR). The primary efficacy endpoint was 6-month angiographic in-stent late lumen loss (LLL). All patients were scheduled to receive angiographic and IVUS follow-up at baseline and 6-months, with 15 patients additionally undergoing OCT analysis at the same time points. All angiographic and clinical data were reviewed and adjudicated by an independent core lab and DSMB at all reported time points. RESULTS After propensity score matching, the baseline clinical characteristics were similar in Absorb BVS and EES groups. As shown in Figure 1 and Table 1 , diabetic patients treated with the BRS had a similar incidence of MACE compared with diabetics treated with EES (5.7% vs. 5.6%, respectively; HR 0.99; 0.44-2.20; P¼0.98) after 393 days of follow-up. 
RESULTS

